Revenues (Tables)

9 Months Ended

Sep. 30, 2021

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue by Product and Geographic Area

Revenues by product line. The following table represents total net revenues by product line:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
Infectious disease testing	$	12,932	$	13,224	$	39,664	$	36,625
Risk assessment testing		2,674		2,253		7,265		6,786
Genomics (1)		19,018		8,454		49,333		23,224
Microbiome (1)		1,693		1,530		5,888		3,869
COVID-19 (1)		13,930		18,867		54,147		27,918
Laboratory services		2,406		2,280		8,017		6,798
Other product and service revenues		576		141		1,235		752
Net product and services revenues		53,229		46,749		165,549		105,972
Royalty income		500		450		2,636		1,623
Other non-product revenues		188		812		1,921		1,271
Other revenues		688		1,262		4,557		2,894
Net revenues	$	53,917	$	48,011	$	170,106	$	108,866

(1) 2020 Genomics, Microbiome, and COVID-19 revenues were reclassified to reflect the correct classification of the product line sales. The reclassification increased (decreased) the product line revenues for the three months ended September 30, 2020 by $(65), $(298), and $363, respectively and increased (decreased) the product line revenue for the nine months ended September 30, 2020 by $(157), $(390), and $547, respectively.

Revenues by geographic area. The following table represents total net revenues by geographic area, based on the location of the customer:


	Three Months Ended September 30,				Nine Months Ended September 30,
	2021		2020		2021		2020
United States	$	42,969	$	38,594	$	139,669	$	82,125
Europe		2,411		2,789		10,288		8,663
Other regions		8,537		6,628		20,149		18,078
	$	53,917	$	48,011	$	170,106	$	108,866